Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 4/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.46 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12412657 | 0.93 | GRM5 (0.66) | GRM5KCNK3KCNK9KMT2AMAPT | |
| SCHEMBL12830277 | 0.90 | GRM5 (0.55) | GRM5KCNQ3KCNQ2 | |
| SCHEMBL12504028 | 0.88 | GRM5 (0.62) | GRM5KCNK3KCNK9KMT2ACYP1A2 | |
| SCHEMBL12412108 | 0.87 | GRM5 (0.67) | GRM5NT5E | |
| SCHEMBL12412167 | 0.87 | GRM5 (0.52) | GRM5MAPTKCNQ3KCNQ2 | |
| SCHEMBL12412660 | 0.87 | GRM5 (0.58) | GRM5CYP3A4 | |
| SCHEMBL12412124 | 0.87 | GRM5 (0.66) | GRM5KCNK3KCNK9KMT2ACYP1A2 | |
| SCHEMBL12412162 | 0.85 | GRM5 (0.65) | GRM5KCNK3KCNK9CYP3A4 | |
| SCHEMBL12412173 | 0.84 | GRM5 (0.62) | GRM5KMT2ACYP1A2CYP3A4GAA | |
| SCHEMBL12412620 | 0.83 | GRM5 (0.67) | GRM5KCNK3KCNK9KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501757-B2 | Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same | VANDERBILT UNIVERSITY (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY | 2011-07-07 | — | — | US | disclosed |
| WO-2011035214-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166158-A1 | SUBSTITUTED PHENYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME | GRM5, GRIK5, GRM2 | GRM5 1/4885KCNK3 1339/4885KCNK9 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.